Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Allergan plc (NYSE:AGN)

172.76
Delayed Data
As of Dec 11
 +4.96 / +2.96%
Today’s Change
160.07
Today|||52-Week Range
256.80
-17.74%
Year-to-Date
Roche Reports Positive Data from Tecentriq Combination Study
Dec 11 / Zacks.com - Paid Partner Content
Revance's Neuromodulator Injection Positive in Phase III
Dec 06 / Zacks.com - Paid Partner Content
Key Feature in Marketks
Dec 11 / TheStreet.com - Paid Partner Content
Levin Capital Strategies, L.p. Buys DowDuPont Inc, Walt Disney Co, Treehouse Foods In...
Dec 06 / GuruFocus News - Paid Partner Content
Weekly CEO Buys Highlight
Dec 11 / GuruFocus News - Paid Partner Content
Why the Latest Data Is a Big Deal for Revance Therapeutics
Dec 05 / GuruFocus News - Paid Partner Content
Weekly Top Insider Buys Highlight for the Week of Dec. 8
Dec 10 / GuruFocus News - Paid Partner Content
Allergan Shares Tumble As Revance Reports Positive Data for Botox Rival
Dec 05 / TheStreet.com - Paid Partner Content
3 Drug/Biotech Stocks Up More Than 10% This Week
Dec 08 / Zacks.com - Paid Partner Content
Building a Circle of Competency
Dec 05 / GuruFocus News - Paid Partner Content
Allergan Plc (AGN) Chairman, President and CEO Brent L Saunders Bought $757,804 of Sh...
Dec 07 / GuruFocus News - Paid Partner Content
Here's Why Sarepta Stock is Up More Than 70% in 6 Months
Dec 05 / Zacks.com - Paid Partner Content
Quick News on Goldman, Allergan
Dec 07 / TheStreet.com - Paid Partner Content
AstraZeneca's COPD Drug Succeeds in Label Expansion Study
Dec 05 / Zacks.com - Paid Partner Content
Outlook for Autodesk: Cramer's Top Takeaways
Dec 06 / TheStreet.com - Paid Partner Content
Ironwood Succeeds in Diabetic Hypertension Phase II Study
Dec 05 / Zacks.com - Paid Partner Content
Allergan Ends Positive After Sell-Off; Walgreens, Fred's Make Moves -- ICYMI
Dec 06 / TheStreet.com - Paid Partner Content
My Former Love Allergan Still Looks Unattractive
Dec 05 / TheStreet.com - Paid Partner Content
U.S. Concrete: Cramer's Top Takeaways
Dec 06 / TheStreet.com - Paid Partner Content
Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%
Nov 28 / Zacks.com - Paid Partner Content
What to Worry About for 2018: Cramer's 'Mad Money' Recap (Wednesday 12/6/17)
Dec 06 / TheStreet.com - Paid Partner Content
Nestl considers fate of past deals before striking again
Nov 14 / FT.com - Paid Partner Content
Roche's Avastin Gets Full FDA Approval for Brain Cancer
Dec 06 / Zacks.com - Paid Partner Content